Acarbose NDC 72789-132

NDC codes

FDA NDC Directory

Product NDC (as listed)72789-132Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72789-0132Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
72789-132-01	72789013201	100 TABLET in 1 BOTTLE, PLASTIC (72789-132-01)Marketed from Jun 24, 2026
72789-132-30	72789013230	30 TABLET in 1 BOTTLE, PLASTIC (72789-132-30)Marketed from Jul 7, 2023
72789-132-60	72789013260	60 TABLET in 1 BOTTLE, PLASTIC (72789-132-60)Marketed from Oct 21, 2020
72789-132-90	72789013290	90 TABLET in 1 BOTTLE, PLASTIC (72789-132-90)Marketed from Sep 16, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acarbose
Generic name (nonproprietary): acarbose
Active ingredients: Acarbose — 50 mg/1
Dosage form: Tablet
Route: Oral
Labeler: PD-Rx Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078470
Marketing start: May 7, 2008
Listing expires: Dec 31, 2027
Other FDA classes: alpha Glucosidase Inhibitors (Mechanism)
Identifiers: Product ID 72789-132_55069653-499d-2f2b-e063-6294a90a1ce9SPL ID 55069653-499d-2f2b-e063-6294a90a1ce9SPL set ID 722ce9eb-8f7b-4651-a287-d53dd7ab3707RxCUI 199149, 199150, 200132UNII T58MSI464GUPC 0372789133010, 0372789131016
Pharmacologic class: alpha-Glucosidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472789013201 followed by a unit qualifier and the quantity

Package 72789-0132-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 24, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Acarbose Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078470

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078470
Product	Strength	Form · route	Labeler	Product NDC
Acarbose	Acarbose 50 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-0141
Acarbose	Acarbose 25 mg/1	TabletOral	PD-Rx Pharmaceuticals, Inc.	72789-131
Acarbose	Acarbose 100 mg/1	TabletOral	PD-Rx Pharmaceuticals, Inc.	72789-133
Acarbose	Acarbose 100 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-0142
Acarbose	Acarbose 25 mg/1	TabletOral	Hikma Pharmaceuticals USA Inc.	0054-0140